pepmg_

Study summary · research use only

The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat

Study · animal · Brain research · 1987 · DOI 10.1016/0006-8993(87)90006-0 · PMID 3620931

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

In this cat study, 10 cats received a single lateral-ventricle injection of synthetic delta-sleep-inducing peptide (DSIP, 7 nmol/kg), and sleep-wake activity was monitored over an 8 h period. DSIP was associated with a significant decrease in sleep latency and a significant increase in total sleep and total slow wave sleep, driven entirely by increased deep slow wave sleep (S2), while light slow wave sleep (S1) significantly decreased. REM sleep totals, REM latency, episode number, and episode length were unchanged from control conditions. S2 increased to more than 50% in the first postinjection hour and stayed elevated over 7 h, returning to baseline by the eighth hour, reflecting prolonged S2 episodes rather than more frequent ones. The authors describe these findings as suggesting a sleep-facilitating property of DSIP.

Abstract

The effect of a single injection of synthetic delta-sleep-inducing peptide (DSIP, 7 nmol/kg) into the lateral ventricle of 10 cats was investigated by monitoring the sleep-wake cycle during an 8 h period. A significant decrease in sleep latency and a significant increase in total sleep and in total slow wave sleep (SWS) was found following DSIP administration. The increase in sleep resulted exclusively from a significant increase in deep slow wave sleep (S2), while light slow wave sleep (S1) was significantly decreased. Neither the total amount of REM sleep, nor hourly values of REM sleep were affected by DSIP application. Additional measures of REM sleep, like REM sleep latency, mean episode number and mean episode length were not different from those found in control conditions. DSIP was immediately effective since the amount of S2 increased to more than 50% in the first postinjection hour and the difference from the control value was highly significant. The increase in S2 was maintained over 7 h, and disappeared by the eighth hour. The increase in S2 was caused by a prolongation of S2 episodes and not by their more frequent occurrence. The results obtained suggest a sleep-facilitating property of DSIP.

Read the full study on PubMed ↗

pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.